Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 4 announced on the evening of April 18 that longpeng investment, a shareholder holding more than 5% of the company, transferred Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) 47098200 shares (accounting for 5% of the total share capital of the company) held by Huzhou Saihan equity investment partnership (limited partnership) (hereinafter referred to as “Huzhou Saihan”) to state-owned background investor Huzhou Saihan equity investment partnership (hereinafter referred to as “Huzhou Saihan”) by agreement, with a transfer price of 13.56 yuan / share and a total transaction price of 639 million yuan.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) said that the transfer of this Agreement reflects Huzhou Saihan’s recognition of the long-term investment value of the listed company and its confidence in the future development prospects.
It is understood that Huzhou Saihan was founded on December 14, 2017, with a registered capital of 1122449 million yuan. Its business scope includes equity investment, investment consulting, asset management and other businesses. Huzhou Jinfu Equity Investment Fund Management Co., Ltd. holds 75.727%, Huzhou Industrial Fund Investment Co., Ltd. holds 22.273%, and Huzhou saishi Investment Management Co., Ltd. holds 2%. The actual controllers of Huzhou Jinfu Equity Investment Fund Management Co., Ltd. and Huzhou Industrial Fund Investment Co., Ltd. are Huzhou SASAC.
In recent years, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) thoroughly implemented the coordinated development of traditional Chinese medicine, chemical medicine and biological medicine and comprehensively developed new R & D concepts, and implemented the comprehensive industrial strategic project by using fixed growth. Based on the advantages of traditional Chinese medicine, the company has rapidly expanded to the field of chemical medicine and biological medicine, driven innovation and R & D, and led the company to achieve high-quality and efficient development. The company also actively seized the historical opportunity of innovative drug R & D, vigorously promoted R & D innovation and accelerated R & D layout.
Relevant insiders said that the Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) introduction of investors with certain capital strength and government resources to realize the complementary advantages between private enterprises and state-owned enterprises will help the company optimize its ownership structure and promote the improvement of its corporate governance structure. While improving the modern governance ability of the company, this move will enable the company to absorb more advanced management concepts and methods, continuously optimize business management, strengthen risk prevention and control, and improve the level of operation and management. In addition, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) can make full use of the resource advantages of state-owned background shareholders and the geographical advantages of the economic development of the Yangtze River Delta, continuously strengthen and expand the pharmaceutical industry with a more open concept and broader platform, better promote the development of traditional Chinese medicine, chemical medicine and biological medicine business, and create a more competitive product pedigree.
